To see all protocols that comply with the WHO Essential Medicine List 
 RVd protocols on eviQ:

There are several RVd protocols on eviQ. This reflects current Australian clinical practice with variations in dosing schedules, indications and treatment intent. Please ensure you are viewing the correct protocol.

eviQ will closely review the clinical need for multiple versions of the RVd protocol to rationalise and consolidate in the future. 

Patients with myeloma should be considered for inclusion into clinical trials. Link to ALLG website and ANZCTR website.

This protocol is based on limited evidence; refer to the evidence section of this protocol for more information.

Link to Medical Scientific Advisory Group (MSAG) Clinical Practice Guideline Multiple Myeloma

Link to MSAG update - bortezomib, lenalidomide and dexamethasone for initial treatment of multiple myeloma

Link to MyeTxScheduler developed by Myeloma Specialist Practice Network of the Haematology Society of Australia and New Zealand Nurses Group

The anticancer drug(s) in this protocol have been updated with the ADDIKD guideline recommendations (if applicable). Recommendations may differ from other protocols which have not been updated. For further information refer to the dedicated eviQ ADDIKD guideline webpage.

The information contained in this protocol is based on the highest level of available evidence and consensus of the eviQ reference committee regarding their views of currently accepted approaches to treatment. Any clinician (medical oncologist, haematologist, radiation oncologist, medical physicist, radiation therapist, pharmacist or nurse) seeking to apply or consult this protocol is expected to use independent clinical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. While eviQ endeavours to link to reliable sources that provide accurate information, eviQ and the Cancer Institute NSW do not endorse or accept responsibility for the accuracy, currency, reliability or correctness of the content of linked external information sources. Use is subject to eviQ’s disclaimer available at www.eviQ.org.au

Send feedback for this page


First approved:
Last reviewed:
Review due:

The currency of this information is guaranteed only up until the date of printing, for any updates please check:

https://www.eviq.org.au/p/3918

29 Mar 2024